Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.

Launched by PRINCE OF SONGKLA UNIVERSITY · Mar 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how different treatments for advanced lung cancer—specifically chemotherapy, targeted therapy, and immunotherapy—affect muscle mass and physical performance in patients. Researchers want to understand if these treatments lead to changes in skeletal muscle mass, which is important because having enough muscle can influence how well a patient does overall. The trial focuses on patients with advanced non-small cell lung cancer, a type of lung cancer that has spread and is harder to treat.

To participate in this study, you must be at least 18 years old and have been diagnosed with advanced lung cancer (stage IIIB, IIIC, or IV). You should also be receiving one of the treatments mentioned above. If you join the trial, you can expect to undergo tests that measure your muscle mass and physical performance before and after your treatment. It is important to note that certain conditions, like not being able to have a CT scan or having other health issues that limit movement, may prevent you from participating. This research could provide valuable insights that help improve care for lung cancer patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age \>18years old,
• • 2. Stage IIIB and IIIC (if patients are treated with TKI/IO), and Stage IV non-small cell lung cancer patients confirmed by histopathology.
• • 3. Patients should be either on chemotherapy, molecular targeted therapy or immunotherapy.
• Exclusion Criteria:
• • 1. Unable to perform CT scan due to various reasons.
• • 2. Patients with metastatic disease at L3 vertebral level.
• • 3. If unable to perform SPPB test due to physical disability or patient's refusal.
• • 4. Patients with known other primary malignancies. 5 . Patients who have underwent definitive surgery.
• • 6. Pregnant patients. 7. Patients with physical deformities/neurological deficits which restricts their physical movements.